Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma

Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma

Pulmonary sarcomatoid carcinoma (PSC), a rare non-small cell lung cancer (NSCLC) subtype, poses diagnostic and treatment difficulties. Current research explores targeted therapies and immunotherapy to improve patient outcomes. This case report details a male patient diagnosed with PSC via pathology....

Full description

Bibliographic Details
Main Authors: Chen-Wei Pu, Yong-Fen Ma, Jing-Jing Peng, Zhen-Zhen Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Oncology
Subjects:
tislelizumab
anlotinib
pulmonary sarcomatoid carcinoma
hemoptysis
adverse effects
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1445358/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1445358/full

Similar Items